KCT0005959尚未招募未知
Postmarketing survey for evaluating the safety, efficacy of MECP in refractory angina patients
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Angina with CCS class >= II 2) administerd with anti-anginal medication 3) ineligible for further PTCA or CABG
排除标准
- •1. deep vein thrombosis or phlebitis
- •2. symptomatic or treatable peripheral artery disease
- •3. moderate or severe valvular heart disease (esp aortic regurgitation)
- •4. moderate or severe pulmonary hypertension (RVSP >50mmHg)
- •5. Aortic aneurysm (diameter > 50mm) or cereberal aneurysm
- •6. uncontrolled hypertension (BP >180/110mmHg)
- •7. decompensted heart failure
- •8. arrhythmia intefering MECP function
- •9. bleeding tendency or severe bleeding history
- •10. acute infection in leg
研究者
相似试验
招募中
4 期
Post Marketing surveillance study to evaluate the safey of liposomal Amphotericine B (Gufisome)inpatient of Invasive fungal infectioCTRI/2022/08/044680Gufic Biosciences Limited
进行中（未招募）
1 期
Jivi interventional PMI study to assess safety and efficacyHemophilia AEUCTR2018-003655-37-ESBayer Consumer Care AG36
进行中（未招募）
1 期
Jivi interventional PMI study to assess safety and efficacyHemophilia AMedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2018-003655-37-DKBayer Consumer Care AG30
进行中（未招募）
1 期
Jivi interventional PMI study to assess safety and efficacyMedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Hemophilia AEUCTR2018-003655-37-GRBayer Consumer Care AG30
进行中（未招募）
1 期
Jivi interventional PMI study to assess safety and efficacyHemophilia AEUCTR2018-003655-37-ITBayer Consumer Care AG30